Packman K - Search Results

1

Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion.

Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh J. Flanagan L, et al. Among authors: packman k. J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):181-92. doi: 10.1016/s0960-0760(03)00028-1. J Steroid Biochem Mol Biol. 2003. PMID: 12711002

2

Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells.

Zhan P, Lee EC, Packman K, Tenniswood M. Zhan P, et al. Among authors: packman k. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):101-11. doi: 10.1016/s0960-0760(02)00275-3. J Steroid Biochem Mol Biol. 2002. PMID: 12650706

3

Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells.

Roy S, Packman K, Jeffrey R, Tenniswood M. Roy S, et al. Among authors: packman k. Cell Death Differ. 2005 May;12(5):482-91. doi: 10.1038/sj.cdd.4401581. Cell Death Differ. 2005. PMID: 15746940

4

Vitamin D(3) receptor ablation alters mammary gland morphogenesis.

Zinser G, Packman K, Welsh J. Zinser G, et al. Among authors: packman k. Development. 2002 Jul;129(13):3067-76. doi: 10.1242/dev.129.13.3067. Development. 2002. PMID: 12070083

5

Antiandrogen-induced cell death in LNCaP human prostate cancer cells.

Lee EC, Zhan P, Schallhom R, Packman K, Tenniswood M. Lee EC, et al. Among authors: packman k. Cell Death Differ. 2003 Jul;10(7):761-71. doi: 10.1038/sj.cdd.4401228. Cell Death Differ. 2003. PMID: 12815459

6

Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model.

Higgins B, Kolinsky K, Linn M, Adames V, Zhang YE, Moisa C, Dugan U, Heimbrook D, Packman K. Higgins B, et al. Among authors: packman k. Anticancer Res. 2007 Jul-Aug;27(4B):2279-87. Anticancer Res. 2007. PMID: 17695515 Free article.

7

Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.

Snyder LA, Damle R, Patel S, Bohrer J, Fiorella A, Driscoll J, Hawkins R, Stratton CF, Manning CD, Tatikola K, Tryputsen V, Packman K, Mamidi RNVS. Snyder LA, et al. Among authors: packman k. Mol Cancer Ther. 2022 Jul 5;21(7):1115-1124. doi: 10.1158/1535-7163.MCT-21-0798. Mol Cancer Ther. 2022. PMID: 35499386

8

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, To KH, Linn M, Podlaski F, Wovkulich P, Vu B, Vassilev LT. Tovar C, et al. Among authors: packman k. Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807. Epub 2013 Feb 11. Cancer Res. 2013. PMID: 23400593

9

Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.

Higgins B, Glenn K, Walz A, Tovar C, Filipovic Z, Hussain S, Lee E, Kolinsky K, Tannu S, Adames V, Garrido R, Linn M, Meille C, Heimbrook D, Vassilev L, Packman K. Higgins B, et al. Among authors: packman k. Clin Cancer Res. 2014 Jul 15;20(14):3742-52. doi: 10.1158/1078-0432.CCR-14-0460. Epub 2014 May 8. Clin Cancer Res. 2014. PMID: 24812409

10

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.

Kolinsky K, Shen BQ, Zhang YE, Kohles J, Dugan U, Zioncheck TF, Heimbrook D, Packman K, Higgins B. Kolinsky K, et al. Among authors: packman k. Mol Cancer Ther. 2009 Jan;8(1):75-82. doi: 10.1158/1535-7163.MCT-08-0596. Mol Cancer Ther. 2009. PMID: 19139115

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters